Overview

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active, biopsy-proven lupus nephritis. The secondary objectives of this study are to assess the safety and tolerability of BIIB023 compared with placebo in this study population.
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
Mycophenolate mofetil
Mycophenolic Acid